Clinical Trials Logo

System; Sclerosis clinical trials

View clinical trials related to System; Sclerosis.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03919799 Terminated - Clinical trials for Diffuse Cutaneous Systemic Sclerosis

KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis

Start date: June 26, 2019
Phase: Phase 2
Study type: Interventional

This randomized, placebo-controlled phase 2 study was seeking to evaluate the efficacy and safety of belumosudil (KD025) for the treatment of diffuse cutaneous systematic sclerosis. Enrolment was terminated earlier than planned for business reasons unrelated to safety. A total of 36 participants were enrolled and randomized into 3 groups to either receive orally administered belumosudil (200 milligrams [mg] once daily [QD] and 200 mg twice daily [BID]) or matched placebo in 1:1:1 ratio in the double-blind (DB) period of this study. Study drug dosing was for 52 weeks: double-blinded for the first 28 weeks followed by an open-label extension of 24 weeks. After unblinding, the participants on belumosudil continued on the same belumosudil dose whereas the participants in the placebo group were re-randomized to one of the belumosudil doses in a 1:1 ratio.